This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
11 Feb 2015

Innovations in Product Design and Materials Brighten Outlook for Non-Vascular Stents Market

Changing lifestyles have led to a rise in gastrointestinal diseases, urological problems, glaucoma and other conditions, which necessitate the use of non-vascular stents. The increase in gastro-urological and respiratory morbidities, in particular, demands the use of non-vascular stents as they can help maintain vessel patency. With the accelerating demand for minimally invasive treatments, which cause less pain, enable faster recovery, and involve shorter hospital stays, the non-vascular stent market is likely to witness encouraging growth trends.

 

New analysis from Frost & Sullivan, Technology Innovations in Non-Vascular Stents, finds that innovations in biodegradable and other materials, unique technological properties of metals and polymers like the capacity to self-expand, and advanced deployment techniques will fuel advances in the non-vascular stents sector.

 

“Material and technology innovations have enabled the development of specially designed stents that can be used for versatile indications,” noted Technical Insights Industry Analyst Debarati Sengupta. “This has increased the diversity of non-vascular stents applications, the size of the target patient pool, and the confidence among physicians using these products.”

 

Key concerns for physicians include complications surrounding stent migration due to forces experienced at the sites of implantation and problems associated with stent removal. The lack of evidence regarding the overall safety of newer designs and materials used to develop non-vascular stents will also restrain market development.

 

As such, the sustained publication of clinical safety information will go a long way in convincing physicians and patients of the safety of non-vascular stents. Physicians and patients must be aware of the latest product developments; for instance, the upcoming introduction of micro-stents in the neural and ophthalmic application segments. Along with this, market participants should efficiently train physicians and surgeons on the way to carry out procedures that require non-vascular stents to boost adoption rates.

 

The premium price tag that non-vascular stents come with will continue to suppress uptake in the short term. However, technological innovations and material improvements are likely to lower the cost of non-vascular stents in the medium- and long-term.

 

“Other major issues surrounding the ease of deployment will also lose relevance as advances in non-vascular stents through proprietary technologies gain pace,” concluded Sengupta. “Ultimately, this will result in the enhanced usage of these products in interventional procedures as well.”

Related News